I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN
Have any thoughts about
Inno-Gene SA?
Write Note

Intrinsic Value

The intrinsic value of one IGN stock under the Base Case scenario is 1.96 PLN. Compared to the current market price of 5.04 PLN, Inno-Gene SA is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IGN Intrinsic Value
1.96 PLN
Overvaluation 61%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
Inno-Gene SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IGN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Inno-Gene SA

Provide an overview of the primary business activities
of Inno-Gene SA.

What unique competitive advantages
does Inno-Gene SA hold over its rivals?

What risks and challenges
does Inno-Gene SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Inno-Gene SA.

Provide P/S
for Inno-Gene SA.

Provide P/E
for Inno-Gene SA.

Provide P/OCF
for Inno-Gene SA.

Provide P/FCFE
for Inno-Gene SA.

Provide P/B
for Inno-Gene SA.

Provide EV/S
for Inno-Gene SA.

Provide EV/GP
for Inno-Gene SA.

Provide EV/EBITDA
for Inno-Gene SA.

Provide EV/EBIT
for Inno-Gene SA.

Provide EV/OCF
for Inno-Gene SA.

Provide EV/FCFF
for Inno-Gene SA.

Provide EV/IC
for Inno-Gene SA.

What are the Revenue projections
for Inno-Gene SA?

How accurate were the past Revenue estimates
for Inno-Gene SA?

What are the Net Income projections
for Inno-Gene SA?

How accurate were the past Net Income estimates
for Inno-Gene SA?

What are the EPS projections
for Inno-Gene SA?

How accurate were the past EPS estimates
for Inno-Gene SA?

What are the EBIT projections
for Inno-Gene SA?

How accurate were the past EBIT estimates
for Inno-Gene SA?

Compare the revenue forecasts
for Inno-Gene SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Inno-Gene SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Inno-Gene SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Inno-Gene SA compared to its peers.

Compare the P/E ratios
of Inno-Gene SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Inno-Gene SA with its peers.

Analyze the financial leverage
of Inno-Gene SA compared to its main competitors.

Show all profitability ratios
for Inno-Gene SA.

Provide ROE
for Inno-Gene SA.

Provide ROA
for Inno-Gene SA.

Provide ROIC
for Inno-Gene SA.

Provide ROCE
for Inno-Gene SA.

Provide Gross Margin
for Inno-Gene SA.

Provide Operating Margin
for Inno-Gene SA.

Provide Net Margin
for Inno-Gene SA.

Provide FCF Margin
for Inno-Gene SA.

Show all solvency ratios
for Inno-Gene SA.

Provide D/E Ratio
for Inno-Gene SA.

Provide D/A Ratio
for Inno-Gene SA.

Provide Interest Coverage Ratio
for Inno-Gene SA.

Provide Altman Z-Score Ratio
for Inno-Gene SA.

Provide Quick Ratio
for Inno-Gene SA.

Provide Current Ratio
for Inno-Gene SA.

Provide Cash Ratio
for Inno-Gene SA.

What is the historical Revenue growth
over the last 5 years for Inno-Gene SA?

What is the historical Net Income growth
over the last 5 years for Inno-Gene SA?

What is the current Free Cash Flow
of Inno-Gene SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Inno-Gene SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Inno-Gene SA

Current Assets 3m
Cash & Short-Term Investments 1.6m
Receivables 1.4m
Other Current Assets 14k
Non-Current Assets 2.5m
Long-Term Investments 1.8m
PP&E 660k
Intangibles 7k
Other Non-Current Assets 72k
Current Liabilities 2.5m
Accounts Payable 376k
Accrued Liabilities 85k
Short-Term Debt 30k
Other Current Liabilities 2m
Non-Current Liabilities 203k
Other Non-Current Liabilities 203k
Efficiency

Earnings Waterfall
Inno-Gene SA

Revenue
462k PLN
Cost of Revenue
-666k PLN
Gross Profit
-204k PLN
Operating Expenses
-2.4m PLN
Operating Income
-2.6m PLN
Other Expenses
-3.5m PLN
Net Income
-6.1m PLN

Free Cash Flow Analysis
Inno-Gene SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IGN Profitability Score
Profitability Due Diligence

Inno-Gene SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Negative Gross Profit
Positive 3-Year Average ROE
Negative 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Inno-Gene SA's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

IGN Solvency Score
Solvency Due Diligence

Inno-Gene SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Average Altman Z-Score
67/100
Solvency
Score

Inno-Gene SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IGN Price Targets Summary
Inno-Gene SA

There are no price targets for IGN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IGN?

Click here to dive deeper.

Dividends

Inno-Gene SA
does not pay dividends
Shareholder Yield

Current shareholder yield for IGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Inno-Gene SA

Country

Poland

Industry

Life Sciences Tools & Services

Market Cap

17.7m PLN

Dividend Yield

0%

Description

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

Contact

WOJ. WIELKOPOLSKIE
Poznan
ul. Sciegiennego 20
www.inno-gene.pl

IPO

2011-02-08

Employees

-

Officers

See Also

Discover More
What is the Intrinsic Value of one IGN stock?

The intrinsic value of one IGN stock under the Base Case scenario is 1.96 PLN.

Is IGN stock undervalued or overvalued?

Compared to the current market price of 5.04 PLN, Inno-Gene SA is Overvalued by 61%.

Back to Top